Journal article
Plasma Lipid Profiling Shows Similar Associations with Prediabetes and Type 2 Diabetes
PJ Meikle, G Wong, CK Barlow, JM Weir, MA Greeve, GL MacIntosh, L Almasy, AG Comuzzie, MC Mahaney, A Kowalczyk, I Haviv, N Grantham, DJ Magliano, JBM Jowett, P Zimmet, JE Curran, J Blangero, J Shaw
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2013
Open access
Abstract
The relationship between lipid metabolism with prediabetes (impaired fasting glucose and impaired glucose tolerance) and type 2 diabetes mellitus is poorly defined. We hypothesized that a lipidomic analysis of plasma lipids might improve the understanding of this relationship. We performed lipidomic analysis measuring 259 individual lipid species, including sphingolipids, phospholipids, glycerolipids and cholesterol esters, on fasting plasma from 117 type 2 diabetes, 64 prediabetes and 170 normal glucose tolerant participants in the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) then validated our findings on 1076 individuals from the San Antonio Family Heart Study (SAFHS). Logis..
View full abstractGrants
Awarded by National Institute of Diabetes and Digestive and Kidney Diseases
Funding Acknowledgements
This work was supported by funding from the Dairy Health and Nutrition Consortium, Australia, The National Health and Medical Research Council of Australia, the OIS Program of the Victorian Government, Australia and by Award Number 1R01DK088972-01 from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the aforementioned funding bodies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The AusDiab study co-coordinated by the Baker IDI Heart and Diabetes Institute, gratefully acknowledges the generous support given by: The National Health and Medical Research Council (NHMRC grant 233200), Australian Government Department of Health and Ageing, the Dairy Health and Nutrition Consortium, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services - Northern Territory, Department of Health and Human Services - Tasmania, Department of Health - New South Wales, Department of Health - Western Australia, Department of Health - South Australia, Department of Human Services - Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag,, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis and sanofi-synthelabo. Also, for their invaluable contribution to the set-up and field activities of AusDiab, we are enormously grateful to A Allman, B Atkins, S Bennett, S Chadban, M de Courten, M Dalton, D Dunstan, T Dwyer, D Jolley, D McCarty, A Meehan, S Murray, P Phillips, C Reid, A Stewart, R Tapp, H Taylor, and F Wilson (Baker IDI Heart and Diabetes Institute). Data collection for the SAFHS was supported by grant P01 HL045522 from the National Institutes of Health (to JB). Additional work was supported by National Institutes of Health awards R01 DK082610 and R01 DK079169 (to JC), and R01 HL091035 (to JB). Parts of this investigation were conducted in facilities constructed with support from Research Facilities Improvement Program grants C06 RR013556 and C06 RR017515 from the National Center for Research Resources of the National Institutes of Health.